


Amendments to the Claims


1. (Original) A fused bicyclic pyrimidine derivative represented by the following general formula (1), or a salt thereof:



wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent (a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆ alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:



wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group


consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms);

R is a hydrogen atom, a C₁ to C₆ alkyl group, a C₁ to C₆ alkylcarbonyl group, or a C₁ to C₆ alkylsulfonyl group;

m is 1 or 2; and

n is 2 or 3.

2. (Original) The fused bicyclic pyrimidine derivative according to claim 1 represented by the following general formula (1a), or a salt thereof:




wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent (a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkyl carbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆

alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms);


R is a hydrogen atom, a C₁ to C₆ alkyl group, a C₁ to C₆ alkylcarbonyl group, or a C₁ to C₆ alkylsulfonyl group; and

n is 2 or 3.

3. (Original) The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:




wherein R¹ is a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxycarbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxycarbonylamino group, a C₁ to C₆ alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.

4. (Original) The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:




wherein X is $-O-$ or $-S(O)_q-$; and q is 0, 1, or 2.

5. (Original) The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is a group represented by the following formula:




wherein R^2 is a hydrogen atom, a C_1 to C_6 alkyl group, a formyl group, a C_1 to C_6 alkylcarbonyl group, a C_1 to C_6 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C_1 to C_6 alkylcarbamoyl group or a C_1 to C_6 alkylsulfonyl group; and r is 1 or 2.

6. (Original) The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:



wherein $R^{2'}$ is an acetyl group or a methylsulfonyl group; and r is 1 or 2.

7. (Original) The fused bicyclic pyrimidine derivative according to claim 2, or a salt thereof, wherein in the general formula (1a), the ring C is represented by the following formula:



8. (Original) The fused bicyclic pyrimidine derivative according to claim 7, or a salt thereof, wherein in the general formula (1a), n is 3.
9. (Original) The fused bicyclic pyrimidine derivative according to claim 7, or a salt thereof, wherein in the general formula (1a), R is a hydrogen atom, and n is 3.
10. (Currently amended) A method for introducing a tachykinin receptor antagonist containing as an active ingredient the in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.
11. (Currently amended) ~~An~~ A method of introducing an NK1 receptor antagonist containing as an active ingredient the in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.
12. (Currently amended) ~~A prophylactic or therapeutic agent for~~ method of preventing or treating dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine, containing as an active ingredient the in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.
13. (Currently amended) ~~A prophylactic or therapeutic agent for~~ method of preventing or treating disorders of digestive tract such as ulcerative colitis and Crohn's disease, containing as an active ingredient the in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.

14. (Currently amended) A ~~prophylactic or therapeutic agent for~~ method of preventing or treating vomiting induced by exposure to X-ray, chemotherapy, pregnancy, migraine, postoperative pains, decreased gastrointestinal motility, and side effects of drugs, ~~containing as an active ingredient the~~ in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.

15. (Currently amended) A ~~therapeutic agent for~~ method of treating conditions, such as asthma, coughing, ache, migraine, tooth pain, and rheumatoid arthritis, ~~containing as an active ingredient the~~ in a patient, which comprises administering to the patient a therapeutically effective amount of a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof.

16. (New) A composition comprising a fused bicyclic pyrimidine derivative according to claim 1, or a salt thereof, and a pharmaceutically acceptable adjuvant.